Starling Oncology annual free cash flow
2020
2021
2022
2023
2024
2025
Starling Oncology Free Cash Flow (FCF) History (STLN)
Starling Oncology reported −$27.8M in free cash flow for fiscal 2025, an increase of $2.5M from the previous fiscal year, with a free cash flow margin of −5.53%.
View full Starling Oncology company overviewStarling Oncology free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$27.8M | $2.5M | — | −5.53% |
| 2024 | 2024-12-31 | −$30.3M | $10.6M | — | −7.71% |
| 2023 | 2023-12-31 | −$40.9M | $26.4M | — | −12.61% |
| 2022 | 2022-12-31 | −$67.3M | −$31.8M | — | −26.65% |
| 2021 | 2021-12-31 | −$35.5M | −$34.8M | — | −17.50% |
| 2020 | 2020-12-31 | −$686,000 | — | — | −0.37% |
Starling Oncology quarterly free cash flow
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $11.0M | $22.4M | — | +6.84% |
| Q1 2026 | 2026-03-31 | −$3.3M | $2.1M | — | −2.21% |
| Q4 2025 | 2025-12-31 | $2.2M | −$258,000 | −10.61% | +1.53% |
| Q3 2025 | 2025-09-30 | −$13.2M | −$13.7M | — | −9.69% |
| Q2 2025 | 2025-06-30 | −$11.4M | $6.1M | — | −9.52% |
| Q1 2025 | 2025-03-31 | −$5.3M | $11.2M | — | −5.09% |
| Q4 2024 | 2024-12-31 | $2.4M | $7.2M | — | +2.42% |
| Q3 2024 | 2024-09-30 | $417,000 | $9.7M | — | +0.42% |
| Q2 2024 | 2024-06-30 | −$17.5M | −$7.9M | — | −17.74% |
| Q1 2024 | 2024-03-31 | −$16.5M | $798,000 | — | −17.42% |
| Q4 2023 | 2023-12-31 | −$4.8M | $11.2M | — | −5.54% |
| Q3 2023 | 2023-09-30 | −$9.2M | $12.3M | — | −11.26% |
| Q2 2023 | 2023-06-30 | −$9.6M | $2.1M | — | −11.96% |
| Q1 2023 | 2023-03-31 | −$17.3M | $692,000 | — | −22.69% |
| Q4 2022 | 2022-12-31 | −$16.0M | $8.2M | — | −22.39% |
| Q3 2022 | 2022-09-30 | −$21.6M | −$18.0M | — | −33.23% |
| Q2 2022 | 2022-06-30 | −$11.7M | −$4.2M | — | −19.24% |
| Q1 2022 | 2022-03-31 | −$18.0M | −$17.8M | — | −32.60% |
| Q4 2021 | 2021-12-31 | −$24.2M | — | — | −46.28% |
| Q3 2021 | 2021-09-30 | −$3.6M | — | — | −6.94% |
| Q2 2021 | 2021-06-30 | −$7.5M | — | — | −15.12% |
| Q1 2021 | 2021-03-31 | −$155,000 | — | — | −0.32% |
Starling Oncology free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$686,000 to −$27.8M, a net decrease of $27.1M. Starling Oncology's latest reported quarter, Q2 2026, generated $11.0M in free cash flow, an increase of $22.4M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Starling Oncology filings at SEC.gov ↗